← 治験一覧に戻る
健康な被験者にラベプラゾールまたはリファンピシンとE7090を併用投与した場合の食物摂取および薬物相互作用の影響を評価する研究
基本情報
- NCT ID
- NCT04565574
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 42
- 治験依頼者名
- Eisai Inc.
概要
This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A \[CYP3A\] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.
対象疾患
Healthy Participants
介入
E7090(DRUG)
Rabeprazole 20 mg(DRUG)
Rifampin 600 mg(DRUG)
依頼者(Sponsor)
エーザイ株式会社(INDUSTRY)